Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Phase 2 Study of Nintedanib for Patients With Advanced Carcinoid Tumors

NCT02399215 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.

NCT NCT02399215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02399215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Phase 2 Study of Nintedanib for Patients With Advanced Carcinoid Tumors
Lead sponsor
Roswell Park Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
May 15, 2015
Completion date
August 31, 2022
Enrollment
32 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoid tumor, metastatic carcinoid tumor, neuroendocrine neoplasm